BioHealth Innovation, Inc. Partner Company Developing Novel Non-Viral Gene Therapies for Treatment of Vascular Diseases.
ROCKVILLE, MARYLAND, July 25, 2017 – Artgen, Inc. is pleased to expand its collaboration with the University of Maryland, Baltimore to advance its preclinical program for ART-101 under the Maryland Industrial Partnerships (MIPS) program. The proposal for "Novel targeted imaging applications for PAD" will be supported by a matching contribution from Artgen under the terms of the MIPS award guidelines.
"It has been a very positive experience to partner with Artgen, Inc. and University of Maryland, Baltimore. This initiative supports the overall mission of BHI to advance and foster innovation and company startups within the Maryland region." said Rich Bendis, BHI President & CEO. "Companies like Artgen are building the next generation of the BioHealth Capital Region (BHCR), and we're looking forward to supporting their continued success."
MIPS promotes the development and commercialization of products and processes through industry/university research partnerships. MIPS provides matching funds to help Maryland companies pay for the university research. Projects are initiated by the companies to meet their own research and development goals.
About Artgen, Inc.
Incorporated in 2014, Artgen is developing novel non-viral gene therapies for treatment of vascular diseases. Their lead product candidate, ART-101 is a DNA plasmid designed to be delivered directly to the site of injured tissue with the first indication directed for peripheral artery disease (PAD). ART-101 expresses Vascular Endothelial Growth Factor (VEGF), one of the key regulators of angiogenesis. Artgen's platform technology has the potential for treatment of other vascular diseases. Artgen is currently licensing IP from the Human Stem Cell Institute https://eng.hsci.ru/home.
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary which supports the transformation of research projects into new business opportunities in partnership with the region's rich assets, institutions, and entrepreneurial community. BHI achieves this goal by being a catalytic partner in the economic development ecosystem. Learn more at www.biohealthinnovation.org.
# # #
Media contacts:
Rich Bendis
Phone: 301-637-6439, email: This email address is being protected from spambots. You need JavaScript enabled to view it.